| scholarly article | Q13442814 |
| P50 | author | Liang-In Lin | Q56418529 |
| Da-Liang Ou | Q59680214 | ||
| Ann-Lii Cheng | Q38639483 | ||
| P2093 | author name string | Jun-Yang Liou | |
| Chiun Hsu | |||
| Ya-Chi Chang | |||
| Bin-Shyun Lee | |||
| P2860 | cites work | Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). | Q53985281 |
| Dissimilar immunohistochemical expression of ERK and AKT between paired biopsy and hepatectomy tissues of hepatocellular carcinoma. | Q54471459 | ||
| Evidence of autocrine regulation in human hepatoma cell lines | Q69828722 | ||
| DNA damage response and growth factor signaling pathways in gliomagenesis and therapeutic resistance | Q26825975 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators | Q28267500 | ||
| Tumor suppressor CHK2: regulator of DNA damage response and mediator of chromosomal stability | Q28298710 | ||
| Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells | Q28299546 | ||
| Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 | ||
| The effects of insulin-like growth factors on tumorigenesis and neoplastic growth | Q33945357 | ||
| IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. | Q34102411 | ||
| Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver | Q35810600 | ||
| An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis | Q35863982 | ||
| Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model. | Q36204972 | ||
| Identification of angiogenic properties of insulin-like growth factor II in in vitro angiogenesis models | Q36621109 | ||
| ??? | Q28256350 | ||
| CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin? | Q37001375 | ||
| Molecular targeted therapies in hepatocellular carcinoma | Q37003665 | ||
| Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma | Q37284612 | ||
| Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives | Q37766798 | ||
| Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology | Q37973047 | ||
| Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates | Q39538508 | ||
| Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma | Q39585554 | ||
| Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling | Q39600616 | ||
| A kinase-independent role for unoccupied insulin and IGF-1 receptors in the control of apoptosis. | Q39622751 | ||
| A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. | Q40616617 | ||
| Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma | Q40860429 | ||
| Characterization of the insulin-like growth factor axis in a human hepatoma cell line (PLC). | Q40981388 | ||
| Increased expression of the insulin-like growth factor I (IGF-I) receptor gene in hepatocellular carcinoma cell lines: implications of IGF-I receptor gene activation by hepatitis B virus X gene product. | Q42519906 | ||
| In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase | Q42799629 | ||
| Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis. | Q42830680 | ||
| Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma | Q43279511 | ||
| An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation | Q44564128 | ||
| A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts | Q45073541 | ||
| The human hepatitis B virus transactivator X gene product regulates Sp1 mediated transcription of an insulin-like growth factor II promoter 4. | Q45755634 | ||
| A novel orthotopic tumor model to study growth factors and oncogenes in hepatocarcinogenesis. | Q46361400 | ||
| Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells | Q46431072 | ||
| Stability of phosphoprotein as a biological marker of tumor signaling | Q46549087 | ||
| Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis | Q46553511 | ||
| Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors | Q47860361 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| preproinsulin | Q7240673 | ||
| P304 | page(s) | e66589 | |
| P577 | publication date | 2013-01-01 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway | |
| P478 | volume | 8 |
| Q36232448 | Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma |
| Q53066756 | Interplay of genetic and epigenetic alterations in hepatocellular carcinoma. |
| Q38862452 | MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine. |
| Q34292802 | Picropodophyllin and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells |
| Q38936589 | Promising new strategies for hepatocellular carcinoma |
| Q52345488 | Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight. |
| Q37413127 | Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma. |
| Q36382520 | Using activation status of signaling pathways as mechanism-based biomarkers to predict drug sensitivity |
Search more.